Brian E Dixon1,2, Kara K Wools-Kaloustian3,4, William F Fadel5, Thomas J Duszynski1, Constantin Yiannoutsos5, Paul K Halverson6,7, Nir Menachemi2,6. 1. Department of Epidemiology, IU Fairbanks School of Public Health, Indianapolis, Indiana, United States of America. 2. Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States of America. 3. Department of Medicine, IU School of Medicine, Indianapolis, Indiana, United States of America. 4. Center for Global Health, Indiana University, Indianapolis, Indiana, United States of America. 5. Department of Biostatistics, IU Fairbanks School of Public Health, Indianapolis, Indiana, United States of America. 6. Department of Health Policy and Management, IU Fairbanks School of Public Health, Indianapolis, Indiana, United States of America. 7. Department of Family Medicine, IU School of Medicine, Indianapolis, Indiana, United States of America.
Abstract
BACKGROUND: Prior studies examining symptoms of COVID-19 are primarily descriptive and measured among hospitalized individuals. Understanding symptoms of SARS-CoV-2 infection in pre-clinical, community-based populations may improve clinical screening, particularly during flu season. We sought to identify key symptoms and symptom combinations in a community-based population using robust methods. METHODS: We pooled community-based cohorts of individuals aged 12 and older screened for SARS-CoV-2 infection in April and June 2020 for a statewide prevalence study. Main outcome was SARS-CoV-2 positivity. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for individual symptoms as well as symptom combinations. We further employed multivariable logistic regression and exploratory factor analysis (EFA) to examine symptoms and combinations associated with SARS-CoV-2 infection. RESULTS: Among 8214 individuals screened, 368 individuals (4.5%) were RT-PCR positive for SARS-CoV-2. Although two-thirds of symptoms were highly specific (>90.0%), most symptoms individually possessed a PPV <50.0%. The individual symptoms most greatly associated with SARS-CoV-2 positivity were fever (OR = 5.34, p<0.001), anosmia (OR = 4.08, p<0.001), ageusia (OR = 2.38, p = 0.006), and cough (OR = 2.86, p<0.001). Results from EFA identified two primary symptom clusters most associated with SARS-CoV-2 infection: (1) ageusia, anosmia, and fever; and (2) shortness of breath, cough, and chest pain. Moreover, being non-white (13.6% vs. 2.3%, p<0.001), Hispanic (27.9% vs. 2.5%, p<0.001), or living in an Urban area (5.4% vs. 3.8%, p<0.001) was associated with infection. CONCLUSIONS: Symptoms can help distinguish SARS-CoV-2 infection from other respiratory viruses, especially in community or urgent care settings where rapid testing may be limited. Symptoms should further be structured in clinical documentation to support identification of new cases and mitigation of disease spread by public health. These symptoms, derived from asymptomatic as well as mildly infected individuals, can also inform vaccine and therapeutic clinical trials.
BACKGROUND: Prior studies examining symptoms of COVID-19 are primarily descriptive and measured among hospitalized individuals. Understanding symptoms of SARS-CoV-2 infection in pre-clinical, community-based populations may improve clinical screening, particularly during flu season. We sought to identify key symptoms and symptom combinations in a community-based population using robust methods. METHODS: We pooled community-based cohorts of individuals aged 12 and older screened for SARS-CoV-2 infection in April and June 2020 for a statewide prevalence study. Main outcome was SARS-CoV-2 positivity. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for individual symptoms as well as symptom combinations. We further employed multivariable logistic regression and exploratory factor analysis (EFA) to examine symptoms and combinations associated with SARS-CoV-2 infection. RESULTS: Among 8214 individuals screened, 368 individuals (4.5%) were RT-PCR positive for SARS-CoV-2. Although two-thirds of symptoms were highly specific (>90.0%), most symptoms individually possessed a PPV <50.0%. The individual symptoms most greatly associated with SARS-CoV-2 positivity were fever (OR = 5.34, p<0.001), anosmia (OR = 4.08, p<0.001), ageusia (OR = 2.38, p = 0.006), and cough (OR = 2.86, p<0.001). Results from EFA identified two primary symptom clusters most associated with SARS-CoV-2 infection: (1) ageusia, anosmia, and fever; and (2) shortness of breath, cough, and chest pain. Moreover, being non-white (13.6% vs. 2.3%, p<0.001), Hispanic (27.9% vs. 2.5%, p<0.001), or living in an Urban area (5.4% vs. 3.8%, p<0.001) was associated with infection. CONCLUSIONS: Symptoms can help distinguish SARS-CoV-2 infection from other respiratory viruses, especially in community or urgent care settings where rapid testing may be limited. Symptoms should further be structured in clinical documentation to support identification of new cases and mitigation of disease spread by public health. These symptoms, derived from asymptomatic as well as mildly infected individuals, can also inform vaccine and therapeutic clinical trials.
Authors: Jane Y Tong; Amanda Wong; Daniel Zhu; Judd H Fastenberg; Tristan Tham Journal: Otolaryngol Head Neck Surg Date: 2020-05-05 Impact factor: 3.497
Authors: Nir Menachemi; Constantin T Yiannoutsos; Brian E Dixon; Thomas J Duszynski; William F Fadel; Kara K Wools-Kaloustian; Nadia Unruh Needleman; Kristina Box; Virginia Caine; Connor Norwood; Lindsay Weaver; Paul K Halverson Journal: MMWR Morb Mortal Wkly Rep Date: 2020-07-24 Impact factor: 17.586
Authors: Mackenzie E Hannum; Riley J Koch; Vicente A Ramirez; Sarah S Marks; Aurora K Toskala; Riley D Herriman; Cailu Lin; Paule V Joseph; Danielle R Reed Journal: Chem Senses Date: 2022-01-01 Impact factor: 3.160
Authors: Carlos Eduardo Covantes-Rosales; Victor Wagner Barajas-Carrillo; Daniel Alberto Girón-Pérez; Gladys Alejandra Toledo-Ibarra; Karina Janice Guadalupe Díaz-Reséndiz; Migdalia Sarahy Navidad-Murrieta; Guadalupe Herminia Ventura-Ramón; Mirtha Elena Pulido-Muñoz; Ulises Mercado-Salgado; Ansonny Jhovanny Ojeda-Durán; Aimée Argüero-Fonseca; Manuel Iván Girón-Pérez Journal: Int J Environ Res Public Health Date: 2022-05-08 Impact factor: 4.614
Authors: A Boscutti; G Delvecchio; A Pigoni; G Cereda; V Ciappolino; M Bellani; P Fusar-Poli; P Brambilla Journal: Brain Behav Immun Health Date: 2021-05-18
Authors: César Fernández-de-Las-Peñas; José D Martín-Guerrero; Lidiane L Florencio; Esperanza Navarro-Pardo; Jorge Rodríguez-Jiménez; Juan Torres-Macho; Oscar J Pellicer-Valero Journal: Infection Date: 2022-04-22 Impact factor: 7.455
Authors: M Antonelli; J Capdevila; A Chaudhari; J Granerod; L S Canas; M S Graham; K Klaser; M Modat; E Molteni; B Murray; C H Sudre; R Davies; A May; L H Nguyen; D A Drew; A Joshi; A T Chan; J P Cramer; T Spector; J Wolf; S Ourselin; C J Steves; A E Loeliger Journal: J Infect Date: 2021-02-13 Impact factor: 6.072